Latest Shire plc Stories
DUBLIN, June 14, 2013 /PRNewswire/ -- Honor extraordinary carers who sacrifice for others The BRAVE Awards, an international awards initiative that recognizes the courage and dedication of non-professional caregivers, is seeking nominations through June 30, 2013. Developed and implemented by Shire plc, the global biopharmaceutical company, the BRAVE Awards honor unpaid, non-professional caregivers who give of themselves in a meaningful, dedicated and selfless manner. Up...
LEXINGTON, Massachusetts, June 11, 2013 /PRNewswire/ -- Shire's Chief Financial Officer, Graham Hetherington will present at the Goldman Sachs 34th Annual Global Healthcare Conference on Wednesday, June 12th at 9:20 AM PT /17:20 BST. Investors may access a live audio webcast of the presentation at http://www.shire.com/shireplc/en/investors. NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on...
LEXINGTON, Massachusetts, May 30, 2013 /PRNewswire/ -- Shire's Chief Executive Officer, Flemming Ornskov, MD will present at the Deutsche Bank 38th Annual Health Care Conference today, May 30th at 10:40 AM EDT/15:40 BST. Investors may access a live audio webcast of the presentation at http://www.shire.com/shireplc/en/investors. NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing...
PHILADELPHIA, May 17, 2013 /PRNewswire/ -- Research explores data on treatments for psychiatric disorders; health economics and outcomes research also to be presented Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association (APA) 166th Annual Meeting in San Francisco, May 18-22. The data being presented...
DUBLIN, May 2, 2013 /PRNewswire/ -- Shire delivers 10% increase in Non GAAP earnings; full year EPS guidance in line with consensus(1) Shire (LSE: SHP, NASDAQ: SHPG) announces results for the three months to March 31, 2013. Reported Financial Highlights Q1 2013 Growth(2) $1,117...
Becomes the first stimulant medication approved for maintenance treatment in patients ages 6 and above with ADHD PHILADELPHIA, May 1, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse(R) (lisdexamfetamine dimesylate) Capsules, (CII) as a maintenance treatment in children and adolescents with...
PHILADELPHIA, April 25, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), announces that its subsidiary, Shire LLC, has settled all pending litigation with Actavis, Inc., Actavis LLC, and Actavis Elizabeth LLC (collectively "Actavis") and Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and ANDA, Inc. (collectively "Watson") in connection with Actavis' and Watson's Abbreviated New Drug Applications ("ANDAs") for generic versions of Shire's INTUNIV(R) ( guanfacine...
International awards program honors non-professional caregivers DUBLIN, Ireland, April 24, 2013 /PRNewswire/ -- The BRAVE Awards, an international awards initiative that recognizes the courage and dedication of non-professional caregivers, is accepting nominations for its 2013 program. Now in its third year, the BRAVE Awards honors those unsung everyday heroes - unpaid, non-professional caregivers - who give of themselves every day in a meaningful, dedicated and selfless...
New findings reveal the substantial burden of rare diseases due to lack of resources, financial challenges and emotional unrest LEXINGTON, Mass., April 9, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today launched a Rare Disease Impact Report, which uncovers the health, psycho-social, and economic impact of rare diseases on patient and medical communities in the United States (US) and United Kingdom (UK). The report, developed in collaboration with an external advisory...
Acquisition brings Shire a new phase 3 compound being investigated for the signs and symptoms of Dry Eye Disease LEXINGTON, Massachusetts, March 25, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it will acquire SARcode Bioscience Inc., a privately held biopharmaceutical company based in Brisbane, California. This acquisition continues to build Shire's presence in the ophthalmology therapeutic category and brings a new phase 3 compound -...
